Overview

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
Phase:
Phase 2
Details
Lead Sponsor:
ICON Bioscience Inc